A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients with Newly Diagnosed and Relapsed/Refractory Cancer Indications

UVA Tracking #
HSR210503
Principal Investigator
Indumathy Varadarajan
Contact
Contact Phone
Official Trial Title
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients with Newly Diagnosed and Relapsed/Refractory Cancer Indications
Study Description

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). If you join this study, you will receive an investigational drug called Eltanexor. The trial will investigate the investigational drug by testing its safety and how your body reacts to the study drug. Each treatment cycle is 28 days. If you have AML, you’ll take the study drug 7 days per week for 21 days each cycle. If you have MDS, you will take the study drug 5 days per week during the entire cycle.

The study also looks into administering this drug as a maintenance therapy to see if this would help you stay in remission after an allogeneic transplant for the leukemia. Please mention details of the regimen if it is different from the pre treatment arm.

Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT02649790

uvacancertrials@hscmail.mcc.virginia.edu

Compensation

Mileage - $.54 cents per mile Hotel – up to $175 per night